Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JSCT-MM26 talquetamab maintenance after transplant-based quadruplet therapy for newly diagnosed multiple myeloma
jRCTs071260071Phase 2Recruiting
- Sponsor
- Kyushu University Hospital
- Start
- Aug 2026
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of talquetamab in multiple myeloma (MM) (2 arms), sponsored by Kyushu University Hospital. Primary endpoint: 12-month MRD-negative complete response after talquetamab maintenance. Started Aug 2026; status: recruiting.
02
Drugs
talquetamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on jRCTs071260071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs071260071.